专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2011157400A Modified vaccinia virus ankara for vaccination of neonate 有权
标题翻译：改良的VACCINIA VIRUS ANKARA用于灭活新生儿
公开(公告)号：JP2011157400A
公开(公告)日：2011-08-18
申请号：JP2011115564
申请日：2011-05-24
申请人： Bavarian Nordic As , バヴァリアン・ノルディック・アクティーゼルスカブ
发明人： CHAPLIN PAUL , SUTER MARK , ACKERMANN MATHIAS , FRANCHINI MARCO , VOLLSTEDT SABINE , HEFTI HANS PETER
IPC分类号： A61K39/12 , A61K39/275 , A61K39/245 , A61K39/285 , A61P31/12 , A61P31/20 , A61P37/06 , C12N7/00
CPC分类号： A61K39/285 , A61K39/12 , A61K39/245 , A61K2039/5254 , A61K2039/55 , A61K2039/58 , C12N7/00 , C12N2710/16634 , C12N2710/24134 , C12N2710/24143 , C12N2710/24151 , C12N2710/24161
摘要： PROBLEM TO BE SOLVED: To provide a means for vaccinating a human neonatal and a neonatal animal against a foreign antigen and an antigen associated with disease of a human and an animal, respectively.
SOLUTION: A virus is used for the production of a medicine for vaccinating or treating a neonatal or prenatal animal, including a human, wherein the virus has capability of infecting a cell of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a modified vaccinia virus Ankara. In particular, vaccination of the neonate is carried out against infections with the virus belonging the same virus group as the virus used for vaccination. Moreover, the vaccination of the neonate is carried out against the antigen selected from a foreign antigen and a tumour antigen, which are different from the antigen associated with the virus. By using the virus, a level of a factor activating a dendritic cell or its precursor cell is increased, the number of the dendritic cell or its precursor cell is increased, and (or) a production amount and (or) a cellular content of an interferon (IFN) or IL-12 are increased.
COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译：要解决的问题：提供一种用于分别针对外来抗原和与人和动物疾病相关的抗原接种人新生儿和新生儿动物的手段。解决方案：病毒用于生产用于疫苗接种或治疗新生儿或产前动物（包括人）的药物，其中病毒具有感染新生儿或产前动物（包括人）的细胞的能力，但是不能在新生儿或产前动物（包括人）中复制感染性后代病毒。病毒优选为修饰的痘苗病毒安卡拉。特别地，对于与用于接种疫苗的病毒相同的病毒组的病毒的感染，进行新生儿的疫苗接种。此外，对与选自外源抗原和肿瘤抗原的抗原进行新生儿接种，所述抗原与肿瘤抗原不同于与病毒相关的抗原。通过使用病毒，激活树突状细胞或其前体细胞的一个因子水平增加，树突细胞或其前体细胞的数量增加，和（或）生产量和（或）细胞内含量干扰素（IFN）或IL-12增加。版权所有（C）2011，JPO＆INPIT

2. 发明专利

JP2010120955A Modified vaccinia virus ankara for vaccination of newborn animal 审中-公开
标题翻译：新生疫苗改良疫苗病毒ANKALA
公开(公告)号：JP2010120955A
公开(公告)日：2010-06-03
申请号：JP2010028940
申请日：2010-02-12
申请人： Bavarian Nordic As , バヴァリアン・ノルディック・アクティーゼルスカブ
发明人： CHAPLIN PAUL , SUTER MARK , ACKERMANN MATHIAS , FRANCHINI MARCO , VOLLSTEDT SABINE , HEFTI HANS PETER
IPC分类号： A61K39/12 , A61K31/7088 , A61K39/00 , A61K39/02 , A61K39/205 , A61K39/21 , A61K39/235 , A61K39/245 , A61K39/275 , A61K39/285 , A61K48/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P31/18 , A61P31/22 , A61P35/00 , A61P37/04 , C12N7/00
CPC分类号： A61K39/285 , A61K39/12 , A61K39/245 , A61K2039/5254 , A61K2039/55 , A61K2039/58 , C12N7/00 , C12N2710/16634 , C12N2710/24134 , C12N2710/24143 , C12N2710/24151 , C12N2710/24161
摘要： PROBLEM TO BE SOLVED: To provide a means for vaccinating a neonatal human and animal against foreign antigens and antigens associated with diseases of human and animal, respectively. SOLUTION: In a method for using a virus for producing a medicament for vaccinating or treating the neonatal or prenatal animal, including the human, the virus has potency to infect the cells of the neonatal or prenatal animal, including the human, but has no potency to be replicated to an infectious progeny virus in the neonatal or prenatal animal, including the human. The virus is preferably a modified vaccinia virus Ankara. Particularly, the vaccination of neonates against infection with viruses belonging to the same virus group as the virus used for vaccination is provided. The vaccination of neonates against antigens selected from foreign antigens and tumor antigens different from antigens associated with the aforesaid virus is also provided. Furthermore, the use of the virus as defined above to increase the level of factors activating dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production amount and/or cellular content of an interferon (IFN) or IL-12 is provided. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：要解决的问题：提供一种手段，分别为新生儿人和动物针对与人类和动物疾病相关的外来抗原和抗原接种疫苗。解决方案：在使用病毒生产用于疫苗接种或治疗新生儿或产前动物（包括人）的药物的方法中，该病毒具有感染新生儿或产前动物（包括人）的细胞的效力，但是在新生儿或产前动物（包括人）中没有潜力复制到感染性后代病毒。病毒优选为修饰的痘苗病毒安卡拉。特别地，提供新生儿针对与用于接种疫苗的病毒相同的病毒组的病毒感染的疫苗接种。还提供了新生儿针对选自外源抗原和不同于与上述病毒相关的抗原的肿瘤抗原的抗原的疫苗接种。此外，如上定义的病毒的使用增加了激活树突状细胞或其前体细胞的因子水平和/或增加树突细胞或其前体细胞的数量和/或增加生产量和/或细胞含量的干扰素（IFN）或IL-12。版权所有（C）2010，JPO＆INPIT

3. 发明专利

NZ711569A Single high dose of mva induces a protective immune response in neonates and infants 未知
公开(公告)号：NZ711569A
公开(公告)日：2021-03-26
申请号：NZ71156914
申请日：2014-03-14
申请人： BAVARIAN NORDIC AS
发明人： CHEMINAY CÉDRIC , CHAPLIN PAUL , VOLKMANN ARIANE , SUTER MARK
IPC分类号： A61K39/165 , A61K39/285
摘要： The invention relates to compositions and methods for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age. The invention encompasses administering a single high dose of at least 10^8 TCID50 of an MVA to a human neonate or infant of less than 6 months of age, wherein the administration induces protective T- and B-cell responses against a poxvirus in the human neonate or infant.

4. 发明专利

SI1420822T2 Modificiran virus vakcinije Ankara za vakcinacijo novorojenčkov 未知
公开(公告)号：SI1420822T2
公开(公告)日：2017-11-30
申请号：SI200330925
申请日：2003-04-16
申请人： BAVARIAN NORDIC AS
发明人： CHAPLIN PAUL , SUTER MARK , ACKERMANN MATHIAS , FRANCHINI MARCO , VOLLSTEDT SABINE , HEFTI HANS PETER
IPC分类号： A61K39/00 , A61K39/12 , A61K39/245 , A61K39/275 , A61K39/285 , A61P31/12 , C12N7/00

5. 发明专利

DK2529010T3 MUTANTER AF VACCINIAVIRUS, DER INDEHOLDER DE VIGTIGSTE GENOMISKE DELETIONER AF MVA 未知
公开(公告)号：DK2529010T3
公开(公告)日：2017-07-24
申请号：DK11701949
申请日：2011-01-28
申请人： BAVARIAN NORDIC AS
发明人： HAUSMANN JUERGEN , MEISINGER-HENSCHEL CHRISTINE , SUTER MARK
IPC分类号： C12N15/86 , A61K39/00 , C12N7/00 , C12N7/02

6. 发明专利

PL220781B1 Zastosowanie wirusa krowianki Ankara (MVA) szczepu MVA-BN 未知
公开(公告)号：PL220781B1
公开(公告)日：2016-01-29
申请号：PL37159403
申请日：2003-04-16
申请人： BAVARIAN NORDIC AS
发明人： CHAPLIN PAUL , SUTER MARK , ACKERMANN MATHIAS , FRANCHINI MARCO , VOLLSTEDT SABINE , HEFTI HANS PETER
IPC分类号： A61K39/12 , A61K39/285 , A61K38/21 , A61K39/00 , A61K39/245 , A61K39/275 , A61P31/12 , A61P37/02 , C12N7/00

7. 发明专利

AU2011209175A1 Vaccinia virus mutants containing the major genomic deletions of MVA 未知
公开(公告)号：AU2011209175A1
公开(公告)日：2012-07-05
申请号：AU2011209175
申请日：2011-01-28
申请人： BAVARIAN NORDIC AS
发明人： HAUSMANN JUERGEN , MEISINGER-HENSCHEL CHRISTINE , SUTER MARK
IPC分类号： C12N7/00 , A61K39/275 , C12N7/02 , C12N15/863
摘要： The present invention provides methods of producing modified vaccinia virus (VACV) genomes and related vectors. The method consists essentially in deleting one or more of the vaccinia genomic regions corresponding to those that are present in the Chorioallantois Vaccinia virus but absent in the Modified Vaccinia Ankara virus. The resulting viruses, vectors and host cells are also disclosed. Moreover, a method for determining the effect of a mutation on a vaccinia virus, using one of the modified vaccinia viruses of the invention, is also contemplated.

8. 发明专利

SG173216A1 MODIFIED VACCINIA VIRUS ANKARA FOR THE VACCINATION OF NEONATES 未知
公开(公告)号：SG173216A1
公开(公告)日：2011-08-29
申请号：SG2007001563
申请日：2003-04-16
申请人： BAVARIAN NORDIC AS
发明人： CHAPLIN PAUL , SUTER MARK , ACKERMANN MATHIAS , FRANCHINI MARCO , VOLLSTEDT SABINE , HEFTI HANS PETER
IPC分类号： A61K39/12 , A61K39/00 , A61K39/245 , A61K39/275 , A61K39/285 , A61P31/12 , C12N7/00 , C12N15/863
摘要： The invention concerns the use of a virus for the preparation of a medicament for thevaccination or treatment of a neonatal or prenatal animal, including a human,wherein the virus is capable of infecting the cells of the neonatal or prenatal animal,including a human, but not capable of being replicated to infectious progeny virus inthe neonatal or prenatal animal, including a human. The virus is preferably aModified Vaccinia Virus Ankara. In particular, the invention concerns the vaccinationof neonates against infections with viruses belonging the same virus group than thevirus used for vaccination. Moreover, the invention concerns the vaccination ofneonates against antigens selected from foreign antigens and tumour antigens,wherein the tumour antigen and/or the foreign antigen are different from the antigensassociated with the virus. The invention further concerns the use of viruses asdefined above to increase the level of factors which activate dendritic cells or theirprecursor cells and/or to increase the number of dendritic cells or their precursorcells and/or to increase the production and/or cellular content of an interferon (IFN)or IL-12.(no suitable figure)

9. 发明专利

AU2003239805B2 Modified vaccinia virus ankara for the vaccination of neonates 未知
公开(公告)号：AU2003239805B2
公开(公告)日：2009-09-10
申请号：AU2003239805
申请日：2003-04-16
申请人： BAVARIAN NORDIC AS
发明人： VOLLSTEDT SABINE , SUTER MARK , FRANCHINI MARCO , ACKERMANN MATHIAS , CHAPLIN PAUL , HEFTI HANS PETER
IPC分类号： A61K39/12 , A61K39/00 , A61K39/245 , A61K39/275 , A61K39/285 , A61P31/12 , C12N7/00
摘要： The invention concern the use of a virus for the preparation of a medicament for the vaccination or treatment of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara. In particular, the invention concerns the vaccination of neonates against infections with viruses belonging the same virus group than the virus used for vaccination. Moreover, the invention concerns the vaccination of neonates against antigens selected from foreign antigens and tumour antigens, wherein the tumour antigen and/or the foreign antigen are different from the antigens associated with the virus. The invention further concerns the use of viruses as defined above to increase the level of factors which activate dendritic cells or their precursor cells and/or to increase the number of dendritic cells or their precursor cells and/or to increase the production and/or cellular content of an interferon (IFN) or IL-12.

10. 发明专利

EA011233B1 ПРИМЕНЕНИЕ МОДИФИЦИРОВАННОГО ВИРУСА ОСПОВАКЦИНЫ АНКАРА ДЛЯ ВАКЦИНАЦИИ НОВОРОЖДЕННЫХ 未知
公开(公告)号：EA011233B1
公开(公告)日：2009-02-27
申请号：EA200401405
申请日：2003-04-16
申请人： BAVARIAN NORDIC AS
发明人： CHAPLIN PAUL , SUTER MARK , ACKERMANN MATHIAS , FRANCHINI MARCO , VOLLSTEDT SABINE , HEFTI HANS PETER
IPC分类号： A61K39/12 , A61K39/285 , A61K39/00 , A61K39/245 , A61K39/275 , A61P31/12 , A61P43/00 , C12N7/00
摘要： Изобретениеотноситсяк применениювирусадляполучениялекарственногопрепаратадлявакцинацииилилеченияживотного, включаячеловека, внеонатальномилипренатальномпериоде, гдевирусспособенинфицироватьклеткиживотного, включаячеловека, внеонатальномилипренатальномпериоде, нонеспособенреплицироватьсяв инфекционноепотомствовирусау животного, включаячеловека, внеонатальномилипренатальномпериоде. ВируспредпочтительнопредставляетсобоймодифицированныйосповакцинныйвирусАнкара. Вчастности, изобретениеотноситсяк вакцинацииноворожденныхпротивинфекций, вызываемыхвирусами, относящимисяк тойжегруппевирусов, чтои вирус, используемыйдлявакцинации. Крометого, изобретениеотноситсяк вакцинацииноворожденныхпротивантигенов, выбранныхизчужеродныхантигенови опухолевыхантигенов, гдеопухолевыйантигени/иличужеродныйантигенотличаютсяотантигенов, связанныхс вирусом. Изобретениедополнительноотноситсяк применениювирусов, определенныхвыше, дляувеличенияконцентрациифакторов, которыеактивируютдендритныеклеткиилиихклетки-предшественники, и/илиувеличенияколичествадендритныхклетокилиихклеток-предшественников, и/илиповышенияпродукциии/иликлеточногосодержанияинтерферона (IFN) или IL-12.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式